Delving into the Latest Updates on SYH-2039 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mat2A

Mechanism

Mat2A inhibitors(S-adenosylmethionine synthase isoform type-2 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [3]

Active Indication

Advanced Malignant Solid NeoplasmMethylthioadenosine phosphorylase deletion cancerAdvanced cancer+ [5]

Inactive Indication-

Originator Organization

CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.

Active Organization

CSPC Pharmaceutical Group Ltd.

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objectives: Evaluate the safety and tolerability of SYH2039 tablets in participants with advanced malignancies Determine the MTD (if any) and RP2D of SYH2039 tablets Secondary objectives: Evaluate the PK characteristics of SYH2039 tablets in participants with advanced malignancies Evaluate the preliminary anti-tumor activity of SYH2039 tablets Evaluate the PD indicators of SYH2039 tablets

Start Date-

Sponsor / Collaborator

CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.

NCT06568614 / Not yet recruitingPhase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SYH2039 Tablets in Adults With Advanced Solid Tumors

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD and preliminary anti-tumor activity of SYH2039 in adult patients with selected advanced or metastatic advanced solid tumors who are unresponsive to standard of care therapy. SYH2039 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Start Date21 Sep 2024

Sponsor / Collaborator

CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.

100 Clinical Results associated with SYH-2039

Login to view more data

100 Translational Medicine associated with SYH-2039

Login to view more data

100 Patents (Medical) associated with SYH-2039

Login to view more data

100 Deals associated with SYH-2039

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	21 Sep 2024
Methylthioadenosine phosphorylase deletion cancer	Phase 1	-	CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.	21 Sep 2024
Advanced cancer	Phase 1	CN	CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.	18 Jul 2024
Bladder Cancer	Preclinical	CN	CSPC Pharmaceutical Group Ltd.	-
Gastrooesophageal junction cancer	Preclinical	CN	CSPC Pharmaceutical Group Ltd.	-
Glioma	Preclinical	CN	CSPC Pharmaceutical Group Ltd.	-
Non-Small Cell Lung Cancer	Preclinical	CN	CSPC Pharmaceutical Group Ltd.	-
Pancreatic Cancer	Preclinical	CN	CSPC Pharmaceutical Group Ltd.	-